GENERALIZED MYASTHENIA GRAVIS

This early-stage study is testing a single dose of an experimental CAR-T cell therapy called YTB323 in people with severe, treatment-resistant myasthenia gravis. The main goals are to see if the treatment is safe and if it can reduce the debilitating muscle weakness caused by the…

This study is testing a drug called inebilizumab in children and teenagers with generalized myasthenia gravis (gMG), a rare autoimmune disease that causes severe muscle weakness. The main goals are to see how the drug behaves in the body and to check its safety. Participants will…

This study is testing a new pill form of a drug called cladribine to see if it can help control symptoms of generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness. Researchers will compare the drug to a placebo in about 264 adults with moderate to sever…

This study is testing an investigational drug called telitacicept to see if it can safely reduce symptoms and improve daily life for adults with generalized myasthenia gravis (gMG), an autoimmune disease that causes severe muscle weakness. About 180 participants will receive eith…

This study is testing a drug called gefurulimab in children and teenagers (ages 6 to 18) who have generalized myasthenia gravis, a condition that causes severe muscle weakness. The main goals are to see how the drug moves through the body, if it is safe, and if it helps reduce sy…

This study is testing several different drug combinations to find the safest and most effective treatments for myasthenia gravis, an autoimmune disease that causes muscle weakness. The trial will enroll about 70 adults who have been diagnosed with this condition and are currently…

This study is testing an investigational drug called rozanolixizumab in children aged 2 to 18 who have moderate to severe generalized myasthenia gravis (gMG), a rare autoimmune disease that causes muscle weakness. The main goal is to see if the drug is safe and well-tolerated whe…

This study is testing whether the drug Ravulizumab can help control symptoms and improve daily life for people with early-stage myasthenia gravis, a condition that causes muscle weakness. Researchers will follow 40 participants for about a year to see how well the drug works in r…

This study is testing a medication called efgartigimod in children and teenagers with generalized myasthenia gravis, a rare autoimmune disease that causes severe muscle weakness. The trial aims to find the right dose for young patients and see how safe and effective it is at cont…

This study is testing an experimental cell therapy called KYV-101 for adults with generalized myasthenia gravis, a disease that causes severe muscle weakness. The therapy, known as CAR T, is designed to reset the immune system by removing harmful B cells that attack the body. Res…

This early-stage study is testing a new drug called cizutamig in 44 adults with generalized myasthenia gravis, a chronic autoimmune disease that causes severe muscle weakness. The main goal is to check if the drug is safe and well-tolerated, while also looking for early signs tha…

This study is testing whether an investigational drug called IMVT-1402 can safely reduce symptoms and improve daily life for adults with generalized myasthenia gravis, a chronic autoimmune disease that causes severe muscle weakness. About 231 participants with mild to severe symp…

This study aims to find the right dose and check the safety of an investigational injection called efgartigimod for children and teenagers (ages 2 to under 18) with generalized myasthenia gravis (gMG), a rare autoimmune disease that causes severe muscle weakness. Participants wil…

This study is testing whether adding a new drug called empasiprubart to an existing treatment (efgartigimod) can better control symptoms of myasthenia gravis. It will involve about 70 adults with a specific type of this muscle-weakening disease who have had only a partial improve…

This study aims to learn about the safety, drug levels in the body, and activity of an investigational drug called zilucoplan in children and teenagers (ages 2 to 18) with a rare autoimmune disease called generalized myasthenia gravis (gMG). The study will enroll about 8 particip…

This study is testing an investigational drug called iptacopan to see if it can help control symptoms and improve daily life for adults with generalized myasthenia gravis (gMG). About 146 participants will take either iptacopan or a placebo pill for 6 months while continuing thei…

This study is testing whether an oral medication called remibrutinib can help control symptoms and improve daily life for adults with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes muscle weakness. About 180 participants who are already on stable st…

This study is creating a worldwide registry to track 500 patients with generalized myasthenia gravis who have received specific antibody treatments. Researchers will collect health information over up to 5 years to understand how these treatments affect patients' daily lives and …